Parliament Workbench
Data: Official Report to 18 Nov 2026

Official Report · Committee

Current Petitions

Low-dose Naltrexone (PE1296)

Tuesday 1 March 2011 Public Petitions Committee About 14:00 Petitions 32 contributions · 8 speakers

Speakers

Choose an MSP to read only their contributions

The record

32 contributions
Rhona Brankin Lab The Convener · Midlothian
link

The next petition is PE1296, by Robert Thomson, on behalf of LDN Now Scotland, on national health service availability of low-dose naltrexone. As the committee agreed on 8 February, we will take evidence on the petition to clarify issues around the process for considering research bids of the nature highlighted in the petition. I welcome from the Scottish Government Professor Bill Scott, chief pharmaceutical officer; Dr Alan McNair, research manager; and Peter Craig, research manager. I invite the committee to ask questions.14:45

Anne McLaughlin SNP Glasgow
link

Good afternoon. When we had an evidence session with the petitioners, we were all struck by their personal testimonies. I think that we took evidence over a year ago—certainly the petition came to us 15 months ago. Since then, I have been contacted by a number of people who have benefited from the use of LDN. As you know—this is the point of the petition—the difficulty is that it is not widely prescribed by general practitioners, which means that people often have to get it by private prescription.There are two issues. One relates to LDN itself, which I will come on to, but there is also a broader question. If, as the petitioners and others have suggested, the pharmaceutical companies are not interested in research, primarily because it is not that profitable, does that mean that it is low cost to the NHS? What other routes to getting that research done could the petitioners go down? They are not medical experts or researchers and they do not have the contact lists. They want LDN because they are suffering from illness. They do not have the money that you would normally need to do this research without the aid of one of the pharmaceutical companies.

Professor Bill Scott Chief Pharmaceutical Officer
link

Where there are large patient populations with unsolved need, the pharmaceutical industry would generally be interested. The profitability then becomes about whether the patient population is large enough for the industry to invest.We met LDN Now at the committee’s request. I think that we had a good meeting. The outcome was probably unsatisfactory for the petitioners in that they did not go away with many solutions. However, all of us in the room agreed that, in order for clinicians to have some sort of faith in LDN as a potential treatment, they need to gather evidence. In order for any product to make its way through to full licensing, there needs to be robust evidence of its effect. It can then proceed through by manufacturers picking it up and applying for a licence. When it has a licence, it can be prescribed within the NHS, provided that the Scottish Medicines Consortium approves or recommends it.What we have at present is a product for which there is no product licence, which has to be prescribed as a special medicine. That means that the prescriber takes greater responsibility for that drug than they would do were it a licensed medicine. As I understand it, the petitioners’ frustration is how you get the evidence if you cannot get the research.Today, my colleagues from the chief scientist office will, I hope, take you through some of that process to see whether we can find some accommodation or even help the petitioners to take things forward. We made it clear to them that, in our opinion, because there is a plethora of diseases in the treatment of which LDN could be used, the best way forward would be to start by focusing on one disease—probably, in common parlance, the low-hanging fruit—on which effect can be demonstrated. Making such a breakthrough would give other researchers confidence to pick up other areas.

Anne McLaughlin SNP Glasgow
link

Did you say that your colleagues were going to take us through how they might help? Although the petition is on the provision of LDN, I would like to know how people who feel that other medicines help can go down the same route.I want to come back on what you said about special medicines and medicines that are not licensed but which can be prescribed. We were given the example of mitoxantrone, which is prescribed as an anti-cancer drug. It is not licensed to be used to treat multiple sclerosis, but it is routinely used for people with MS. The petitioners asked why, given that that is the case with that drug, it cannot be the case with this one. Moreover, naltrexone, which is 10 times the strength of low-dose naltrexone and is toxic, is routinely prescribed and is licensed. For me, that is quite confusing. I am interested to find out about those seeming contradictions.

Professor Scott
link

If a clinician prescribes a medicine off licence, they take responsibility for that. That responsibility is wider than it would be if they were prescribing a licensed medicine, so there is an additional risk.There is the licensed product naltrexone, but there is no formulation of a low-dose naltrexone. It would be for manufacturers to determine whether they wanted to look into producing a low-dose formulation and having it licensed. A new medicine would have to be created from the existing medicine, which is why a special manufacturer would be required to produce it.

Anne McLaughlin SNP Glasgow
link

I take the point that if pharmaceutical companies think that there is a big enough body of people out there to allow them to make money, they will produce it, but is that not just an admission that their primary interest is profit? They are private companies, so that is likely to be the case. If LDN is not a high-cost product, it will not be highly profitable. It is fair enough to say that it is up to manufacturers to produce it, but will they do so? The petitioners’ argument is that they will not, because it is not that profitable.

Professor Scott
link

I cannot say whether profit is the only thing that the industry thinks about. There are some social issues that are taken into account in the suite of medicines that they produce or in their areas of interest. In the past, we have had examples of cases in which special medicines that have been made up on the order of individual clinicians have been taken up by the industry. Sometimes, those are no longer cheap or low-cost medicines, because producing them to that level for licensing requires an incredible amount of investment. The industry sets a cost that is realistic relative to its economic investment in producing the new formulation.

Anne McLaughlin SNP Glasgow
link

Notwithstanding my point that there are wider issues than those to do with a single drug, I would not have thought that the process would be terrifically expensive, given that we have naltrexone. However, I am not a pharmacist and do not know how to produce lower-dose medicines.You said that your colleagues would come on to explain the route that people can take if they cannot get pharmaceutical companies interested.

Dr Alan McNair Scottish Government Directorate for Chief Medical Officer, Public Health and Sport
link

I concur with Professor Scott. For any medicine to be adopted, we need to have proof of its safety and, importantly, its efficacy. The most appropriate manner in which to determine that is through a clinical trial. As the petitioners have pointed out, naltrexone is a fairly old drug and is no longer under patent, so it is unlikely that a pharmaceutical company would invest resources to allow a clinical trial to take place using that particular drug.Other routes to fund research or clinical trials are through Government or charity funding. In Scotland, the chief scientist office has the remit of funding biomedical research, and we certainly fund clinical trials. If someone wants to apply to us for funding, we ask only that the principal investigator on the study is a Scotland-based academic, either at a university or in an NHS board. Apart from that, we are totally non-prescriptive. If the petitioners approached a researcher, they could apply to us for funding.

Rhona Brankin Lab The Convener · Midlothian
link

Dr Craig, do you want to add anything?

Dr Peter Craig Scottish Government Directorate for Chief Medical Officer, Public Health and Sport
link

No—that is the situation as it applies to the chief scientist office.

Anne McLaughlin SNP Glasgow
link

The petitioners have said that they cannot afford to obtain a marketing authorisation to apply for the drug to be licensed, as it costs about £200,000. If they went down the route that Dr McNair describes, would they have to do that? I understand that they are speaking to a Scotland-based academic who might be able to assist them, but would they then have to find something in the region of £200,000?

Dr McNair
link

The petitioners would need to get ethical approval and research governance approval for the study, but those costs would be met from the grant that would be awarded, so there would be no onus on them to find any financial contribution to those processes.

John Wilson SNP Central Scotland
link

Professor Scott referred to clinicians prescribing off licence. I have a constituent whose GP will give medication off licence. However, no other GP in the practice or the practice nurse will give that medication because it is off licence. The petitioners have asked for guidance to be given to GPs on LDN so that they understand how it can be used to treat patients who request it. My concern for that constituent is that, if they require another GP because the current one retires or for some other reason, that other GP would not administer the drug, which would be detrimental to the individual patient. If a patient who has been receiving the drug finds that no other clinician, GP or practice nurse is prepared to administer it, how do they get access to it?

Professor Scott
link

I understand the dilemma, but the Medicines Act 1968 is clear that the prescribing of any medicine is the responsibility of the individual clinician. For an unlicensed medicine, there is an additional responsibility. The clinician must weigh up the need for that medicine against the fact that it is not licensed.15:00

John Wilson SNP Central Scotland
link

We are talking about the administration of a licensed drug that is off licence in terms of the number of injections that are received. I am trying to get clarification on that point. The current guidance places restrictions on how often the drug should be administered, but an individual GP or clinician may decide to administer it more often than the guidance prescribes.

Professor Scott
link

Where a medicine must be made up by the pharmacy, there is an obligation on the clinician who orders it to take responsibility for its quality and safety. Clinicians must weigh up such matters against patient benefit.

Anne McLaughlin SNP Glasgow
link

Is methotrexate a drug that is prescribed for some auto-immune disorders? Someone contacted me to say that it is off licence, which makes it sound like I am buying alcohol. Although significant side effects and costs are associated with methotrexate and there is limited previous experience of its use for auto-immune conditions, doctors seem happy to prescribe it, but they are not happy to prescribe LDN. The person who contacted me suggested that pharmaceutical companies are promoting methotrexate more heavily. There must be a procedure that GPs follow when they decide which medicines they will prescribe off licence. What is the difference between a GP’s deciding to prescribe methotrexate, which has side effects, as I mentioned, and is more costly, and their deciding to prescribe LDN?

Professor Scott
link

Earlier, you talked about marketing authorisation, which authorises pharmaceutical companies to promote medicines to the clinical community. Where they do not have authorisation for an unlicensed medicine, they cannot promote it. I do not see how the industry can be promoting methotrexate for unlicensed use.

Anne McLaughlin SNP Glasgow
link

That has been suggested as the reason why methotrexate is used more. What reason would you suggest?

Professor Scott
link

I cannot comment on individual cases, as I do not know them. Generally, methotrexate is a medicine with which you must be careful, but general practitioners may be taking advice from consultants who are experts in the field. At the end of the day, it is for general practitioners to determine what the advice is and to take responsibility. One issue in relation to LDN is that there is a paucity of data about efficacy, which probably gives clinicians another dimension to take into account.

Anne McLaughlin SNP Glasgow
link

That is an interesting answer. The petition asks the Scottish Government“to provide guidance to all GPs on LDN protocol and require them to collect LDN clinical data.”The petitioners have anecdotal evidence on the issue, but they agree that there is a lack of data. In their view, when they get private prescriptions for LDN because they cannot get it from their GP, they are spending a lot of money to keep themselves well, so that they can continue to work and to contribute to society, which is saving us money in the long run. They are having to go through all that. The petitioners are saying, “We believe it works. We know that there needs to be evidence, but there are barriers in the way of collecting the evidence.” One of the things that the petitioners are looking for is for the Government to ask GPs to collect clinical data. Perhaps that could be considered, as a way forward for the petition.

Professor Scott
link

We would not promote an unlicensed product or unlicensed use of a product. In the context of Scottish Government policy, we advocate the use of medicines in a cost-effective way, where there is an evidence base.I come back to our starting point. We had the conversation with LDN Now, in which we suggested that it major on one indication to start with, and we offered assistance in the creation of an application in that regard. I think that Dr Gilhooly was enthusiastic about taking the idea forward and was looking for a clinical researcher to tie up with. The offer to get the application in is still open. Applications go to an expert panel, which gives advice if it thinks that a trial could do with some improvement.

Dr McNair
link

The two research committees in the CSO receive in excess of 300 applications per annum and any application that comes to us goes for external expert review. The review is fed back to the applicants, even if they are unsuccessful, so it provides a useful framework for further development of the application.

Anne McLaughlin SNP Glasgow
link

What annual budget is available for successful applications?

Dr McNair
link

The maximum that we can give out for any one project is £225,000. The total research budget for the two committees is around the £10 million mark. We are not a huge funder. Let me put that into context: Cancer Research UK’s annual research budget is in excess of £300 million.

Anne McLaughlin SNP Glasgow
link

I know. I used to work for Cancer Research UK, raising some of those funds.Would £225,000 be enough to enable LDN Now to conduct the research that it needs to conduct if it is to get to where it wants to be?

Dr McNair
link

A sum of £225,000 is probably at the lower limit of what is needed to conduct a full randomised clinical trial.The Scottish Government, through the CSO, also contributes in the region of £6 million per annum to the Office for Strategic Co-ordination of Health Research, which runs the National Institute for Health Research health technology assessment programme. I think that the budget per application for that is unlimited.We regard our role as being to fund pilot trials to allow evidence to be gathered, which, if appropriate, could lead to a successful application to something like the HTA programme.

Rhona Brankin Lab The Convener · Midlothian
link

Thank you; that was helpful. I invite suggestions from members on what to do with the petition.

Anne McLaughlin SNP Glasgow
link

In the debate in the Parliament last week on the work of the Public Petitions Committee, I suggested that in future we should invite petitioners to contribute to evidence sessions. I am feeling the frustration of not having that happen today.We have heard what we already knew: an application could be progressed for a limited budget for a pilot trial, which could lead to something else. The issue is of great interest to me, but I am not sure what the Public Petitions Committee can do with the petition. I would be interested to talk to LDN Now after this meeting, but I am not sure that there is an awful lot that the committee can do, other than to be aware of the matter, as individuals, and to look forward to receiving progress reports.We should congratulate the petitioners on raising awareness not only of LDN but of the wider issue of the difficulty that red tape can cause patients when they try to access treatments that they have found to work for them.

Rhona Brankin Lab The Convener · Midlothian
link

The suggestion is that we should close the petition. Do members agree?Members indicated agreement.

Rhona Brankin Lab The Convener · Midlothian
link

I thank our witnesses for their attendance.

  1. 14:00 Current Petitions Petitions · 27
  2. 14:00 Current Petitions Petitions · 32
  3. 14:00 Current Petitions Petitions · 3
  4. 14:00 Current Petitions Petitions · 4
  5. 14:00 Current Petitions Petitions · 37
  6. 14:00 Current Petitions Petitions · 4
  7. 14:00 Current Petitions Petitions · 5
  8. 14:00 Current Petitions Petitions · 3
  9. 14:00 Current Petitions Petitions · 9

The type of each item (debate, statement, questions, members’ business and so on) and the times shown are worked out by this site from headings, the chair’s opening words and the Official Report’s running timestamps. They are not the Parliament’s own classification. Text: the Scottish Parliament Official Report.